{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:56:36Z","timestamp":1792079796499,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/M009513\/1"],"award-info":[{"award-number":["BB\/M009513\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015652","name":"Barts Charity","doi-asserted-by":"publisher","award":["G-002392"],"award-info":[{"award-number":["G-002392"]}],"id":[{"id":"10.13039\/100015652","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Conditions like fibrosis, rheumatoid arthritis or cancer, once seen as distinct diseases, are now recognized to share strikingly common pathogenic mechanisms. The key to this convergence lies in the fibroblast, a pivotal driver of disease progression, tissue injury and chronicity. Despite this central pathogenic role and growing recognition as a therapeutic target, effective treatments targeting fibroblasts remain elusive, leaving a critical gap in disease intervention.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Here we present a novel approach to target fibrosis using the melanocortin compound BMS-470539 to treat in vitro cultured human dermal fibroblasts obtained from healthy volunteers and systemic sclerosis patients and measuring various markers of senescence and fibroblast activation combining microscopy, DNA sequencing, cell migration and RNA sequencing and PCR techniques. We also used the in vivo bleomycin induced skin fibrosis in mice to determine pre-clinical efficacy of BMS-470539.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>BMS-470539 induced a \u2018senescence-like\u2019 state in human dermal fibroblasts from systemic sclerosis patients, characterised by proliferation arrest, lack of pro-inflammatory secretome and inability to induce secondary senescence. This senescence-like activity (accompanied by \u03b2-galactosidase activity, lipofuscin accumulation and other markers) resulted in the downregulation of fibrosis markers including \u237a-smooth muscle actin, migration, CCL2 and genes related to TGF\u03b2 and fibroblast activation. In vivo, the compound reduced skin thickness on the bleomycin-induced skin fibrosis murine model when administered intraperitoneally, and importantly, this senescence-like activity did not cause signs of fibrosis when administered intradermally.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Here, we introduce a novel strategy to disarm pathogenic fibroblasts in the context of skin fibrosis using a therapeutic pro-senescence-like approach using the unconventional melanocortin compound BMS-470539, to reset fibroblast behaviour and disrupt disease progression. This work also emphasizes the translational potential of how understanding shared pathogenic mechanisms across diseases may lead to new therapeutic opportunities to manage multiple diseases like arthritis and fibrosis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13075-025-03635-3","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T10:27:30Z","timestamp":1759228050000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The senescence-like activity of BMS-470539 is associated with anti-fibrotic actions in models of dermal fibrosis"],"prefix":"10.1186","volume":"27","author":[{"given":"Camilla SA","family":"Davan-Wetton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalya","family":"Khodeneva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Denton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Perretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinidad","family":"Montero-Melendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"10","key":"3635_CR1","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41584-024-01154-0","volume":"20","author":"VM Holers","year":"2024","unstructured":"Holers VM, Demoruelle KM, Buckner JH, James EA, Firestein GS, Robinson WH, et al. Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis. Nat Rev Rheumatol. 2024;20(10):601\u201313.","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"3635_CR2","doi-asserted-by":"publisher","first-page":"e648","DOI":"10.1016\/S2665-9913(23)00241-2","volume":"5","author":"F Rivellese","year":"2023","unstructured":"Rivellese F, Nerviani A, Giorli G, Warren L, Jaworska E, Bombardieri M, et al. Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials. Lancet Rheumatol. 2023;5(11):e648\u201359.","journal-title":"Lancet Rheumatol"},{"issue":"4","key":"3635_CR3","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/s41591-022-01717-2","volume":"28","author":"J Mateo","year":"2022","unstructured":"Mateo J, Steuten L, Aftimos P, Andre F, Davies M, Garralda E, et al. Delivering precision oncology to patients with cancer. Nat Med. 2022;28(4):658\u201365.","journal-title":"Nat Med"},{"issue":"5","key":"3635_CR4","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1016\/S2665-9913(21)00111-9","volume":"3","author":"CP Denton","year":"2021","unstructured":"Denton CP, Khanna D. Rational repurposing of Tocilizumab for treatment of lung fibrosis in systemic sclerosis. Lancet Rheumatol. 2021;3(5):e321\u20133.","journal-title":"Lancet Rheumatol"},{"issue":"11","key":"3635_CR5","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/s41590-021-01044-7","volume":"22","author":"CD Buckley","year":"2021","unstructured":"Buckley CD, Chernajovsky L, Chernajovsky Y, Modis LK, O\u2019Neill LA, Brown D, et al. Immune-mediated inflammation across disease boundaries: breaking down research silos. Nat Immunol. 2021;22(11):1344\u20138.","journal-title":"Nat Immunol"},{"issue":"12","key":"3635_CR6","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/s41584-018-0112-7","volume":"14","author":"SG Dakin","year":"2018","unstructured":"Dakin SG, Coles M, Sherlock JP, Powrie F, Carr AJ, Buckley CD. Pathogenic stromal cells as therapeutic targets in joint inflammation. Nat Rev Rheumatol. 2018;14(12):714\u201326.","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"3635_CR7","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/s12276-023-01013-0","volume":"55","author":"D Yang","year":"2023","unstructured":"Yang D, Liu J, Qian H, Zhuang Q. Cancer-associated fibroblasts: from basic science to anticancer therapy. Exp Mol Med. 2023;55(7):1322\u201332.","journal-title":"Exp Mol Med"},{"key":"3635_CR8","doi-asserted-by":"publisher","first-page":"1084394","DOI":"10.3389\/fimmu.2022.1084394","volume":"13","author":"N Khodeneva","year":"2022","unstructured":"Khodeneva N, Sugimoto MA, Davan-Wetton CSA, Montero-Melendez T. Melanocortin therapies to resolve fibroblast-mediated diseases. Front Immunol. 2022;13:1084394.","journal-title":"Front Immunol"},{"issue":"1","key":"3635_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrrheum.2012.190","volume":"9","author":"N Bottini","year":"2013","unstructured":"Bottini N, Firestein GS. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat Rev Rheumatol. 2013;9(1):24\u201333.","journal-title":"Nat Rev Rheumatol"},{"key":"3635_CR10","doi-asserted-by":"crossref","unstructured":"Lagares D, Santos A, Grasberger PE, Liu F, Probst CK, Rahimi RA et al. Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis. Sci Transl Med. 2017;9(420).","DOI":"10.1126\/scitranslmed.aal3765"},{"issue":"5","key":"3635_CR11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41573-025-01190-9","volume":"24","author":"F Rieder","year":"2025","unstructured":"Rieder F, Nagy LE, Maher TM, Distler JHW, Kramann R, Hinz B, et al. Publisher Correction: Fibrosis: cross-organ biology and pathways to development of innovative drugs. Nat Rev Drug Discov. 2025;24(5):399.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"3635_CR12","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41467-020-14421-x","volume":"11","author":"T Montero-Melendez","year":"2020","unstructured":"Montero-Melendez T, Nagano A, Chelala C, Filer A, Buckley CD, Perretti M. Therapeutic senescence via GPCR activation in synovial fibroblasts facilitates resolution of arthritis. Nat Commun. 2020;11(1):745.","journal-title":"Nat Commun"},{"issue":"7","key":"3635_CR13","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1021\/jm025600i","volume":"46","author":"TF Herpin","year":"2003","unstructured":"Herpin TF, Yu G, Carlson KE, Morton GC, Wu X, Kang L, et al. Discovery of tyrosine-based potent and selective melanocortin-1 receptor small-molecule agonists with anti-inflammatory properties. J Med Chem. 2003;46(7):1123\u20136.","journal-title":"J Med Chem"},{"issue":"1","key":"3635_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s12079-020-00596-x","volume":"15","author":"X Shi-Wen","year":"2021","unstructured":"Shi-Wen X, Racanelli M, Ali A, Simon A, Quesnel K, Stratton RJ, et al. Verteporfin inhibits the persistent fibrotic phenotype of lesional scleroderma dermal fibroblasts. J Cell Commun Signal. 2021;15(1):71\u201380.","journal-title":"J Cell Commun Signal"},{"issue":"7","key":"3635_CR15","doi-asserted-by":"publisher","first-page":"e0306275","DOI":"10.1371\/journal.pone.0306275","volume":"19","author":"CSA Davan-Wetton","year":"2024","unstructured":"Davan-Wetton CSA, Montero-Melendez T. An optimised protocol for the detection of lipofuscin, a versatile and quantifiable marker of cellular senescence. PLoS ONE. 2024;19(7):e0306275.","journal-title":"PLoS ONE"},{"issue":"2","key":"3635_CR16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ad.2013.10.001","volume":"105","author":"MM Pena-Vilabelda","year":"2014","unstructured":"Pena-Vilabelda MM, Garcia-Casado Z, Requena C, Traves V, Lopez-Guerrero JA, Guillen C, et al. Clinical characteristics of patients with cutaneous melanoma according to variants in the melanocortin 1 receptor gene. Actas Dermosifiliogr. 2014;105(2):159\u201371.","journal-title":"Actas Dermosifiliogr"},{"issue":"5","key":"3635_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/cm.21437","volume":"75","author":"SM Nalluri","year":"2018","unstructured":"Nalluri SM, O\u2019Connor JW, Virgi GA, Stewart SE, Ye D, Gomez EW. TGFbeta1-induced expression of Caldesmon mediates epithelial-mesenchymal transition. Cytoskeleton (Hoboken). 2018;75(5):201\u201312.","journal-title":"Cytoskeleton (Hoboken)"},{"issue":"1","key":"3635_CR18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/ehf2.14571","volume":"11","author":"Y Higuchi","year":"2024","unstructured":"Higuchi Y, Ogata T, Nakanishi N, Nishi M, Tsuji Y, Tomita S, et al. Cavin-2 promotes fibroblast-to-myofibroblast trans-differentiation and aggravates cardiac fibrosis. ESC Heart Fail. 2024;11(1):167\u201378.","journal-title":"ESC Heart Fail"},{"issue":"6","key":"3635_CR19","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1096\/fj.07-083857","volume":"22","author":"H Yu","year":"2008","unstructured":"Yu H, Konigshoff M, Jayachandran A, Handley D, Seeger W, Kaminski N, et al. Transgelin is a direct target of TGF-beta\/Smad3-dependent epithelial cell migration in lung fibrosis. FASEB J. 2008;22(6):1778\u201389.","journal-title":"FASEB J"},{"issue":"8","key":"3635_CR20","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1161\/CIRCRESAHA.120.318124","volume":"128","author":"JP Monteiro","year":"2021","unstructured":"Monteiro JP, Rodor J, Caudrillier A, Scanlon JP, Spiroski AM, Dudnakova T, et al. MIR503HG loss promotes Endothelial-to-Mesenchymal transition in vascular disease. Circ Res. 2021;128(8):1173\u201390.","journal-title":"Circ Res"},{"issue":"5","key":"3635_CR21","doi-asserted-by":"publisher","first-page":"L696","DOI":"10.1152\/ajplung.00322.2009","volume":"298","author":"O Mungunsukh","year":"2010","unstructured":"Mungunsukh O, Griffin AJ, Lee YH, Day RM. Bleomycin induces the extrinsic apoptotic pathway in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2010;298(5):L696\u2013703.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"3","key":"3635_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2174\/156800909788166501","volume":"9","author":"M Kasper","year":"2009","unstructured":"Kasper M, Barth K. Bleomycin and its role in inducing apoptosis and senescence in lung cells - modulating effects of caveolin-1. Curr Cancer Drug Targets. 2009;9(3):341\u201353.","journal-title":"Curr Cancer Drug Targets"},{"key":"3635_CR23","doi-asserted-by":"crossref","unstructured":"de la Torre BG, Albericio F. The pharmaceutical industry in 2023: an analysis of FDA drug approvals from the perspective of molecules. Molecules. 2024;29(3).","DOI":"10.3390\/molecules29030585"},{"issue":"3","key":"3635_CR24","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41584-024-01217-2","volume":"21","author":"DJ Abraham","year":"2025","unstructured":"Abraham DJ, Black CM, Denton CP, Distler JHW, Domsic R, Feghali-Bostwick C, et al. An international perspective on the future of systemic sclerosis research. Nat Rev Rheumatol. 2025;21(3):174\u201387.","journal-title":"Nat Rev Rheumatol"},{"key":"3635_CR25","doi-asserted-by":"publisher","first-page":"102267","DOI":"10.1016\/j.pupt.2023.102267","volume":"83","author":"A Joannes","year":"2023","unstructured":"Joannes A, Voisin T, Morzadec C, Letellier A, Gutierrez FL, Chiforeanu DC, et al. Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with progressive fibrosing interstitial lung diseases (PF-ILDs). Pulm Pharmacol Ther. 2023;83:102267.","journal-title":"Pulm Pharmacol Ther"},{"key":"3635_CR26","doi-asserted-by":"publisher","first-page":"107666","DOI":"10.1016\/j.pharmthera.2020.107666","volume":"217","author":"BA Teicher","year":"2021","unstructured":"Teicher BA. TGFbeta-Directed therapeutics: 2020. Pharmacol Ther. 2021;217:107666.","journal-title":"Pharmacol Ther"},{"issue":"18","key":"3635_CR27","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1073\/pnas.1702750114","volume":"114","author":"MJ Bollong","year":"2017","unstructured":"Bollong MJ, Yang B, Vergani N, Beyer BA, Chin EN, Zambaldo C, et al. Small molecule-mediated Inhibition of myofibroblast transdifferentiation for the treatment of fibrosis. Proc Natl Acad Sci U S A. 2017;114(18):4679\u201384.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3635_CR28","doi-asserted-by":"crossref","unstructured":"Khanna D, Padilla C, Tsoi LC, Nagaraja V, Khanna PP, Tabib T et al. Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial. JCI Insight. 2022;7(17).","DOI":"10.1172\/jci.insight.159566"},{"key":"3635_CR29","doi-asserted-by":"publisher","first-page":"107575","DOI":"10.1016\/j.pharmthera.2020.107575","volume":"212","author":"DJ Tschumperlin","year":"2020","unstructured":"Tschumperlin DJ, Lagares D. Mechano-therapeutics: targeting mechanical signaling in fibrosis and tumor stroma. Pharmacol Ther. 2020;212:107575.","journal-title":"Pharmacol Ther"},{"issue":"7","key":"3635_CR30","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1007\/s00018-020-03746-x","volume":"78","author":"CSA Davan-Wetton","year":"2021","unstructured":"Davan-Wetton CSA, Pessolano E, Perretti M, Montero-Melendez T. Senescence under appraisal: hopes and challenges revisited. Cell Mol Life Sci. 2021;78(7):3333\u201354.","journal-title":"Cell Mol Life Sci"},{"issue":"6","key":"3635_CR31","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/nm.4324","volume":"23","author":"OH Jeon","year":"2017","unstructured":"Jeon OH, Kim C, Laberge RM, Demaria M, Rathod S, Vasserot AP, et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat Med. 2017;23(6):775\u201381.","journal-title":"Nat Med"},{"issue":"7","key":"3635_CR32","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/10480","volume":"5","author":"K Taniguchi","year":"1999","unstructured":"Taniguchi K, Kohsaka H, Inoue N, Terada Y, Ito H, Hirokawa K, et al. Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis. Nat Med. 1999;5(7):760\u20137.","journal-title":"Nat Med"},{"issue":"5","key":"3635_CR33","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0092-8674(00)81902-9","volume":"88","author":"M Serrano","year":"1997","unstructured":"Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic Ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997;88(5):593\u2013602.","journal-title":"Cell"},{"issue":"1","key":"3635_CR34","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.1038\/s41467-018-07825-3","volume":"9","author":"Y Ovadya","year":"2018","unstructured":"Ovadya Y, Landsberger T, Leins H, Vadai E, Gal H, Biran A, et al. Impaired immune surveillance accelerates accumulation of senescent cells and aging. Nat Commun. 2018;9(1):5435.","journal-title":"Nat Commun"},{"key":"3635_CR35","doi-asserted-by":"publisher","first-page":"101275","DOI":"10.1016\/j.smim.2019.04.003","volume":"40","author":"L Prata","year":"2018","unstructured":"Prata L, Ovsyannikova IG, Tchkonia T, Kirkland JL. Senescent cell clearance by the immune system: emerging therapeutic opportunities. Semin Immunol. 2018;40:101275.","journal-title":"Semin Immunol"},{"issue":"9\u201310","key":"3635_CR36","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1101\/gad.349585.122","volume":"36","author":"K Yin","year":"2022","unstructured":"Yin K, Patten D, Gough S, de Barros Goncalves S, Chan A, Olan I, et al. Senescence-induced endothelial phenotypes underpin immune-mediated senescence surveillance. Genes Dev. 2022;36(9\u201310):533\u201349.","journal-title":"Genes Dev"},{"key":"3635_CR37","doi-asserted-by":"publisher","first-page":"101412","DOI":"10.1016\/j.arr.2021.101412","volume":"70","author":"TD Admasu","year":"2021","unstructured":"Admasu TD, Rae M, Stolzing A. Dissecting primary and secondary senescence to enable new senotherapeutic strategies. Ageing Res Rev. 2021;70:101412.","journal-title":"Ageing Res Rev"},{"key":"3635_CR38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2147\/OARRR.S50009","volume":"6","author":"CM Artlett","year":"2014","unstructured":"Artlett CM. Animal models of systemic sclerosis: their utility and limitations. Open Access Rheumatol. 2014;6:65\u201381.","journal-title":"Open Access Rheumatol"},{"key":"3635_CR39","doi-asserted-by":"publisher","first-page":"14532","DOI":"10.1038\/ncomms14532","volume":"8","author":"MJ Schafer","year":"2017","unstructured":"Schafer MJ, White TA, Iijima K, Haak AJ, Ligresti G, Atkinson EJ, et al. Cellular senescence mediates fibrotic pulmonary disease. Nat Commun. 2017;8:14532.","journal-title":"Nat Commun"},{"issue":"12","key":"3635_CR40","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.molmed.2024.05.012","volume":"30","author":"S O\u2019Reilly","year":"2024","unstructured":"O\u2019Reilly S, Tsou PS, Varga J. Senescence and tissue fibrosis: opportunities for therapeutic targeting. Trends Mol Med. 2024;30(12):1113\u201325.","journal-title":"Trends Mol Med"},{"issue":"7","key":"3635_CR41","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/ncb2070","volume":"12","author":"JI Jun","year":"2010","unstructured":"Jun JI, Lau LF. The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing. Nat Cell Biol. 2010;12(7):676\u201385.","journal-title":"Nat Cell Biol"},{"issue":"17","key":"3635_CR42","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0960-9822(99)80420-5","volume":"9","author":"DN Shelton","year":"1999","unstructured":"Shelton DN, Chang E, Whittier PS, Choi D, Funk WD. Microarray analysis of replicative senescence. Curr Biol. 1999;9(17):939\u201345.","journal-title":"Curr Biol"},{"issue":"6","key":"3635_CR43","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.devcel.2014.11.012","volume":"31","author":"M Demaria","year":"2014","unstructured":"Demaria M, Ohtani N, Youssef SA, Rodier F, Toussaint W, Mitchell JR, et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev Cell. 2014;31(6):722\u201333.","journal-title":"Dev Cell"},{"issue":"4","key":"3635_CR44","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cell.2008.06.049","volume":"134","author":"V Krizhanovsky","year":"2008","unstructured":"Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, Miething C, et al. Senescence of activated stellate cells limits liver fibrosis. Cell. 2008;134(4):657\u201367.","journal-title":"Cell"},{"issue":"1","key":"3635_CR45","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1046\/j.0022-202X.2003.22121.x","volume":"122","author":"T Yamamoto","year":"2004","unstructured":"Yamamoto T, Nishioka K. Possible role of apoptosis in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol. 2004;122(1):44\u201350.","journal-title":"J Invest Dermatol"},{"key":"3635_CR46","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.semcdb.2019.12.008","volume":"101","author":"W Merkt","year":"2020","unstructured":"Merkt W, Bueno M, Mora AL, Lagares D. Senotherapeutics: targeting senescence in idiopathic pulmonary fibrosis. Semin Cell Dev Biol. 2020;101:104\u201310.","journal-title":"Semin Cell Dev Biol"},{"issue":"1\u20132","key":"3635_CR47","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cell.2017.11.033","volume":"172","author":"AS Hauser","year":"2018","unstructured":"Hauser AS, Chavali S, Masuho I, Jahn LJ, Martemyanov KA, Gloriam DE, et al. Pharmacogenomics of GPCR drug targets. Cell. 2018;172(1\u20132):41\u201354. e19.","journal-title":"Cell"},{"issue":"1","key":"3635_CR48","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13075-017-1252-x","volume":"19","author":"N Quillinan","year":"2017","unstructured":"Quillinan N, Clark KE, Youl B, Vernes J, McIntosh D, Haq S, et al. Multiplex serum protein analysis reveals potential mechanisms and markers of response to hyperimmune caprine serum in systemic sclerosis. Arthritis Res Ther. 2017;19(1):45.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"3635_CR49","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13075-022-02899-3","volume":"24","author":"M Kondo","year":"2022","unstructured":"Kondo M, Suzuki T, Kawano Y, Kojima S, Miyashiro M, Matsumoto A, et al. Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis. Arthritis Res Ther. 2022;24(1):210.","journal-title":"Arthritis Res Ther"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03635-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03635-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03635-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:30:16Z","timestamp":1759275016000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-025-03635-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3635"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03635-3","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Human dermal fibroblasts derived from healthy volunteers and from systemic sclerosis (SSc) patients were kindly provided by Professor David J Abraham and Professor Christopher P Denton (University College London, UCL). The study was approved by the NRES Committee, London-Hampstead, Health Research Authority, Research Ethics Committee London Centre, reference 6398, and all subjects gave written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"187"}}